WO2001077350A3 - Compositions and methods for inhibiting gene expression - Google Patents
Compositions and methods for inhibiting gene expression Download PDFInfo
- Publication number
- WO2001077350A3 WO2001077350A3 PCT/US2001/011436 US0111436W WO0177350A3 WO 2001077350 A3 WO2001077350 A3 WO 2001077350A3 US 0111436 W US0111436 W US 0111436W WO 0177350 A3 WO0177350 A3 WO 0177350A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- present
- eukaryotic cell
- endogenous gene
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001253255A AU2001253255A1 (en) | 2000-04-07 | 2001-04-04 | Compositions and methods for inhibiting gene expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54557400A | 2000-04-07 | 2000-04-07 | |
US09/545,574 | 2000-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001077350A2 WO2001077350A2 (en) | 2001-10-18 |
WO2001077350A3 true WO2001077350A3 (en) | 2002-08-08 |
Family
ID=24176765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011436 WO2001077350A2 (en) | 2000-04-07 | 2001-04-04 | Compositions and methods for inhibiting gene expression |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001253255A1 (en) |
WO (1) | WO2001077350A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6586661B1 (en) | 1997-06-12 | 2003-07-01 | North Carolina State University | Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid |
AU2001297906B2 (en) * | 2000-10-31 | 2007-07-19 | Commonwealth Scientific And Industrial Research Organisation | Method and means for producing barley yellow dwarf virus resistant cereal plants |
WO2004033620A2 (en) | 2001-11-02 | 2004-04-22 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
US20040009946A1 (en) | 2002-05-23 | 2004-01-15 | Ceptyr, Inc. | Modulation of PTP1B expression and signal transduction by RNA interference |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
AU2002951347A0 (en) * | 2002-09-09 | 2002-09-26 | Benitec Australia Ltd | Genetic silencing |
CA2521649C (en) | 2003-04-07 | 2013-05-28 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
WO2005097207A2 (en) | 2004-03-26 | 2005-10-20 | Curis, Inc. | Rna interference modulators of hedgehog signaling and uses thereof |
EP2289534B1 (en) | 2004-04-05 | 2017-08-30 | The Regents of The University of California | NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease |
EP2359842A1 (en) | 2004-07-14 | 2011-08-24 | University of Utah Research Foundation | Netrin-related compositions and uses |
US20060063208A1 (en) | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
EP1866414B9 (en) | 2005-03-31 | 2012-10-03 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
CA2683559C (en) | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
EP3486653A1 (en) | 2007-05-24 | 2019-05-22 | The United States Government as represented by The Department of Veterans Affairs | Treatment of skeletal muscle disorder using ent2 |
JP2011516065A (en) | 2008-04-04 | 2011-05-26 | カランド ファーマシューティカルズ, インコーポレイテッド | Compositions and uses of EPAS1 inhibitors |
US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
IT1398977B1 (en) | 2009-06-25 | 2013-03-28 | Icgeb | ANTI-PANT AGENT SPECIFIC FOR CEREBRAL CANCERS WITH RECQ1 SUPPRESSION MECHANISM |
GB201103167D0 (en) | 2011-02-24 | 2011-04-06 | Isis Innovation | Gene silencing |
EP3738974A1 (en) | 2012-09-28 | 2020-11-18 | The University of North Carolina at Chapel Hill | Aav vectors targeted to oligodendrocytes |
US10300073B2 (en) | 2014-10-14 | 2019-05-28 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
CA2975734A1 (en) | 2015-02-06 | 2016-08-11 | The University Of North Carolina At Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
US20180036404A1 (en) | 2015-03-02 | 2018-02-08 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
CA3031818A1 (en) | 2016-07-27 | 2018-02-01 | Case Western Reserve University | Compounds and methods of promoting myelination |
WO2018106782A1 (en) | 2016-12-08 | 2018-06-14 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
AU2020216480A1 (en) * | 2019-01-31 | 2021-09-09 | Oregon Health & Science University | Methods for using transcription-dependent directed evolution of AAV capsids |
-
2001
- 2001-04-04 WO PCT/US2001/011436 patent/WO2001077350A2/en active Application Filing
- 2001-04-04 AU AU2001253255A patent/AU2001253255A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
ROGERS S A ET AL: "ANALYSIS OF CHLOROPLAST PROMOTERS USING BIDIRECTIONAL TRANSCRIPTION VECTORS", PLANT MOLECULAR BIOLOGY, NIJHOFF PUBLISHERS, DORDRECHT, NL, vol. 15, no. 3, 1990, pages 421 - 435, XP002159238, ISSN: 0167-4412 * |
SPICER D B ET AL: "AN ANTISENSE PROMOTER OF THE MURINE C-MYC GENE IS LOCALIZED WITHIN INTRON 2", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 12, no. 3, March 1992 (1992-03-01), pages 1324 - 1329, XP002910389, ISSN: 0270-7306 * |
SUREAU ALAIN ET AL: "Characterization of multiple alternative RNAs resulting from antisense transcription of the PR264/SC35 splicing factor gene.", NUCLEIC ACIDS RESEARCH, vol. 25, no. 22, 15 November 1997 (1997-11-15), pages 4513 - 4522, XP002197926, ISSN: 0305-1048 * |
VELHAGEN IRIS ET AL: "An antisense promoter within the hepatitis B virus X gene.", INTERVIROLOGY, vol. 38, no. 3-4, 1995, pages 127 - 133, XP008002810, ISSN: 0300-5526 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001077350A2 (en) | 2001-10-18 |
AU2001253255A1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001077350A3 (en) | Compositions and methods for inhibiting gene expression | |
DK1017803T3 (en) | Expression of endogenous genes by non-homologous recombination of a vector construct with cellular DNA | |
ATE220722T1 (en) | CONTROLLED EXPRESSION OF TRANSGENIC CONSTRUCTS IN PLANT PLASTIDS | |
WO1995034668B1 (en) | The cytoplasmic inhibition of gene expression | |
WO2007109131A3 (en) | Lentiviral vectors that provide improved expression and reduced variegation after transgenesis | |
WO2001036623A3 (en) | Ecdysone-inducible adeno-associated virus expression vectors | |
BR0210452A (en) | Gene sd1 involved in plant seminanism and uses of this | |
WO2002101061A3 (en) | Method for obtaining a monocotyledon plant containing a gene of interest free of foreign ancillary sequence | |
DE69735264D1 (en) | CHILDREN'S PROTECTION PROTEINS OF CHORISTONEURA SP., GENES AND METHOD OF USE THEREOF | |
WO2000049162A8 (en) | Compositions and methods for non-targeted activation of endogenous genes | |
ATE525473T1 (en) | CONSTITUTIVE EXPRESSION CASSETTE FOR REGULATING EXPRESSION IN PLANTS. | |
WO2004022782A3 (en) | Compositions and methods for tissue specific or inducible inhibition of gene expression | |
DE50310378D1 (en) | NEW SELECTION PROCEDURES | |
ATE446364T1 (en) | ROOT-SPECIFIC STIMULANT-INDUCABLE PROMOTER AND USE THEREOF | |
WO2000075279A3 (en) | Nucleotide sequences for gene regulation and methods of use thereof | |
CA2487290A1 (en) | Ehd1 gene promoting plant flowering and utilization thereof | |
WO2002083867A3 (en) | Ires enabled gene trapping in plants | |
WO2001094604A3 (en) | Method of using dna episomes to suppress gene expression in plants | |
WO2002028893A3 (en) | Plant cyclin-dependent kinase inhibitors | |
WO2000008189A3 (en) | Plant resistance gene | |
AU2294102A (en) | Mutant muscle-specific enhancers | |
ATE525474T1 (en) | EXPRESSION CASSETTES FOR PREFERENTIAL EXPRESSION IN PLANT ROOTS | |
WO2002016621A3 (en) | Constitutive promoter from arabidopsis | |
CA2478969A1 (en) | Early inflorescence-preferred regulatory elements and uses thereof | |
WO2004104174A3 (en) | Polyubiquitin rubi3 promoter and 5' regulatory sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |